Jagan Lisa, Zoroquiain Pablo, Bravo-Filho Vasco, Logan Patrick, Qutub Mohammed, Burnier Miguel N
Henry C Witelson Ocular Pathology Laboratory, Department of Ophthalmology, McGill University, Montreal, Quebec, Canada.
Br J Ophthalmol. 2015 Jul;99(7):909-13. doi: 10.1136/bjophthalmol-2014-305873. Epub 2015 Jan 16.
BACKGROUND/AIMS: Sebaceous adenomas (SAs) are rare, benign sebaceous gland tumours of the eyelid. SAs may be associated with primary internal malignancies. This association is known as Muir-Torre Syndrome (MTS). The purpose of this study was to approximate the prevalence of SAs, to determine the reliability of the clinical diagnosis of SAs and to demonstrate immunohistochemical staining of DNA mismatch repair proteins mutL homologue 1 (MLH1) and mutS homologue 2 (MSH2) for a case of MTS.
We reviewed the histopathology reports from all eyelid specimens collected between 1993 and 2013 at the Henry C Witelson Ocular Pathology Laboratory to determine the proportion of SAs. For the SAs identified on histopathology, we looked at patient charts to see what diagnosis was originally suspected on clinical examination. Immunohistochemical staining for MLH1 and MSH2 was performed on all SAs to screen for MTS.
Of the 5884 eyelid specimens collected, 9 were SAs (6 women, 3 men; 42-72 years old). The diagnosis of SA was suspected clinically in only one of the nine cases based on the gross appearance of the eyelid lesion. Immunohistochemistry revealed one SA case with positive MLH1 expression and negative MSH2 expression. These findings prompted systemic work-up and this patient was diagnosed with MTS after discovery of a colon adenocarcinoma T2M0N0.
The diagnosis of eyelid SA is rare. The importance of this benign eyelid tumour stems from its association with internal malignancies in MTS. Immunohistochemical staining of mismatch repair proteins MLH1 and MSH2 is a valid and accessible strategy for investigating MTS in patients with SAs.
背景/目的:皮脂腺腺瘤(SA)是一种罕见的眼睑良性皮脂腺肿瘤。SA可能与原发性内脏恶性肿瘤相关。这种关联被称为穆尔-托里综合征(MTS)。本研究的目的是估算SA的患病率,确定SA临床诊断的可靠性,并展示一例MTS患者DNA错配修复蛋白mutL同源物1(MLH1)和mutS同源物2(MSH2)的免疫组化染色情况。
我们回顾了1993年至2013年间在亨利·C·维特尔森眼病理实验室收集的所有眼睑标本的组织病理学报告,以确定SA的比例。对于组织病理学确诊为SA的病例,我们查看患者病历,了解临床检查最初怀疑的诊断。对所有SA进行MLH1和MSH2的免疫组化染色,以筛查MTS。
在收集的5884份眼睑标本中,有9例为SA(6名女性,3名男性;年龄42 - 72岁)。9例中只有1例根据眼睑病变的大体外观在临床上怀疑为SA诊断。免疫组化显示1例SA病例MLH1表达阳性,MSH2表达阴性。这些发现促使进行全身检查,该患者在发现结肠腺癌T2M0N0后被诊断为MTS。
眼睑SA的诊断罕见。这种良性眼睑肿瘤的重要性源于其与MTS中内脏恶性肿瘤的关联。错配修复蛋白MLH1和MSH2的免疫组化染色是调查SA患者MTS的一种有效且可行的策略。